So far, it has been reported that more than 40 inhibitors have targeted UBA1, aminoacylation and nadylation, including the nadylation inhibitor Pevonilistat, which has been evaluated in more than 30 clinical trials, the clinical success of inhibitors in cancer treatment and the emergence of resistance to these drugs have prompted exploration of other signalling nodes in the ubiquitin proteasome system, including E1 enzymes.8 Here, UBA1 is linked to cancer.